Catalyst

Slingshot members are tracking this event:

Seattle Genetics Expects to Complete Enrollment in the Phase 3 ECHELON-2 Trial in Frontline Mature T-cell Lymphoma (MTCL) During 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SGEN

100%
TKPYY

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 08, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Echelon-2 Trial, Phase 3, T-cell Lymphoma, Adcetris, Frontline Mtcl